New Resource Provides Global On-Demand Access to Educational Tools, Training, Problem Solving and Support for Medical Practices

NASHUA, N.H. (May 05, 2015) – iCAD, Inc. (NASDAQ: ICAD),  an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the launch of an enhanced eBx® Institute including a new online learning and support platform for Xoft® Electronic Brachytherapy (eBx) System® users. eBx Institute will offer healthcare providers access to training modules and educational resources to support the treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers using the Xoft System. The web-based solution provides an array of on-demand, self-paced learning programs, including instructional courses and reference materials.

“eBx Institute significantly enhances our customer support and education offering to medical practices, enabling them to deliver the highest level of treatment quality and service to their patients. We are pleased to expand our range of training resources, while ensuring the tool is easily navigated by all users,” said Ken Ferry, CEO of iCAD. “eBx Institute offers physicians and other staff members the opportunity to directly access the robust eBx educational platform from their desktop computers, laptops and mobile devices at any time.”

eBx Institute will enable customers to:

  • Self-enroll in training
  • Search for online course offerings
  • Manage course enrollments
  • View/print transcripts and training certificates upon course completion
  • Review supplemental training materials
  • Watch instructional procedure videos and online simulations

Xoft System users may consult the available information for a variety of different purposes including pre-requisite training, continuing education and post-ILT (instructor-led training) reference. The site also provides information to customers and addresses questions.

“The launch of eBx Institute is a clear example of our ongoing efforts to continually anticipate and meet the needs of our customers with the most advanced technologies and support programs. We will continue to develop and launch targeted training modules and resources to reflect our focus on a more proactive, customer-centric learning environment,” added Mr. Ferry.

To enroll in eBx Institute, Xoft System users may visit, or for more information.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or or

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at


For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030 /7024


For iCAD media inquiries:

Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881